Get AI Briefings, Transcripts & Alerts on Local & National Government Meetings — Forever.
Committee hears broad support for ending 'fail-first' policies for stage‑4 cancer
Loading...
Summary
HB 11-14 would prohibit step‑therapy (fail‑first) requirements for patients with metastatic cancer and associated conditions; oncologists, patient advocates and health groups told the committee the policy reduces dangerous treatment delays and should apply to associated treatment side effects.
Representative Prior presented HB 11-14, a narrowly focused bill to prohibit step therapy (also known as “fail‑first”) for people with stage‑4 metastatic cancer and for conditions directly associated with their cancer treatment.
Clinicians and cancer advocates emphasized the bill’s purpose of preventing potentially life-threatening delays. "Patients and their providers should have the opportunity to choose their best course of treatment," Representative Prior said. The Indiana Oncology Society, Livestrong, Susan G. Komen and Hoosier Breast Cancer Advocates testified that step‑therapy protocols can delay appropriate, individualized care and that associated conditions (treatment side effects such as severe nausea, blood clots, bone loss, infection risk and others) must be treated promptly so patients can remain on life‑prolonging regimens.
Health-plan representatives said they were largely neutral and that implementation details — including definitions of "associated conditions" and any fiscal effects on state employee plans — would require follow-up with fiscal staff. The committee agreed to hold the bill for a week to allow fiscal and drafting checks before moving forward.
Next steps: sponsors will work with insurers and fiscal staff to clarify definitions and any budgetary consequences prior to further committee action.
